Salute e Benessere

BioArctic: Interim Report for the period April - June 2025

Events during the second quarter 2025 Events during the second quarter 2025 Events after the end of the second quarter Financial summary April –June 2025 Comments from the CEO "We are already starting to deliver on our newly launched ambitions for 2030." It has been an eventful and very positive period since our last report. We have seen strong data for Leqembi, a clear increase in sales, continued progress in our development portfolio, and successfully held our...
PR Newswire
28/08/2025

IBA reports strong Half Year 2025 results, transforming towards a more…

Read the entire half year 2025 results press release hereLouvain-la-Neuve, Belgium, 28 August 2025- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the first half of 2025. High revenue growth and improved profitability in H1 driven by accelerated backlog conversionNet sales rose 40% vs. H1 2024, to EUR 304.9 million, with IBA Clinical and IBA Technologies increasing by 47% and 30%...
Nasdaq GlobeNewswire
28/08/2025

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway…

Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. In addition, the company will host a live investor Q&A on September 8, 2025, following the American Heart Association's (AHA) Hypertension Scientific Sessions.TRYVIO is the first systemic...
Nasdaq GlobeNewswire
28/08/2025

SD Biosensor Listed in WHO's Official Recommendation, Strengthening Its Global…

▶ Innovative 3-Tube Design Reduces Required Blood Volume While Enhancing Speed and Efficiency— Optimized for High-Throughput and Large-Scale Testing ▶ Innovative 3-Tube Design Reduces Required Blood Volume While Enhancing Speed and Efficiency — Optimized for High-Throughput and Large-Scale Testing SEOUL, South Korea , Aug. 28, 2025 /PRNewswire/ -- SD Biosensor, Inc. (KQ137310), a global leader inin-vitrodiagnostics fromSouth Korea, announced that its latent tuberculosis (TB)...
PR Newswire
28/08/2025

BIOVAXYS ANNOUNCES UNSECURED CONVERTIBLE DEBENTURE OFFERING AND CANCELLATION OF…

The Debentures will be unsecured obligations of the Company, mature August 30, 2026 (the "Maturity Date"), and bear interest at a rate of 10% per annum with such interest payable on a quarterly basis in either cash or, at the sole discretion of the Company, in common shares of the Company ("Shares"). The principal outstanding under the Debentures will be convertible into Shares at any time, at the option of the holder, at the closing price of the Shares on the Canadian…
PR Newswire
28/08/2025

Androgen Receptor Targeted Therapies Market Forecast: Key Trends and Growth…

Androgen Receptor Targeted Therapies Market Summary Androgen Receptor Targeted Therapies Market Summary Discover which indication is expected to grab the major androgen receptor targeted therapies market share @Androgen Receptor Targeted Therapies Market Report Key Factors Driving the Growth of the Androgen Receptor Targeted Therapies Market Rising prostate cancer burden and ageing populations Prostate cancer incidence rises strongly with age; global population aging...
PR Newswire
27/08/2025

Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading…

Diffuse Large B-cell Lymphoma Market Report Summary Diffuse Large B-cell Lymphoma Market Report Summary Discover more about the diffuse large B-cell lymphoma treatment market @Diffuse Large B-cell Lymphoma Medication Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market Increasing DLBCL Incidence and Aging Population Global DLBCL incidence exceeds150,000cases annually, driven by aging populations (9% aged 65+). In the 7MM, incident cases are...
PR Newswire
27/08/2025

Acarpia Farmaceutici and EarlyHealth Group Expand Their Partnership to Improve…

Building on more than 10 years of collaboration across the Middle East and Turkey, the two companies will now introduce key therapies in rheumatology diseases and cardiovascular care to support both public healthcare systems and private sector providers in the Caribbean and Mexico.Francesco Lapeyre, Chief Operating Officer of Acarpia, commented, “We are proud to expand our partnership with EarlyHealth Group into CARICOM regions and Mexico. By working together to accelerate registration and...
Nasdaq GlobeNewswire
27/08/2025

Innocan Pharma Announces First Half Of 2025 Financial Results

"Despite a challenging market environment in the first half of 2025, we remain fully focused on executing our strategic vision across multiple target markets delivering effective, month-long relief from chronic pain for both humans and animals, with an opioid-free alternative, In addition, our Consumer Wellness segment presents significant opportunities for future growth. "Despite a challenging market environment in the first half of 2025, we remain fully focused on executing our…
PR Newswire
27/08/2025

Ipsen - July 2025 - Monthly information relative to the total number of voting…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 July 2025 83,814,526 Gross total*...
Nasdaq GlobeNewswire
27/08/2025

Ramsay Sante : Provisional annual Results at the end of June 2025

PRESS RELEASE Paris, 27 thAugust 2025 Provisional annual results at the end of June 2025 Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long term financing frameworkActivity growth and cost control mitigate low French tariffs Group revenue increased by 4.7% to €5.2bn supported by activity volume growth and former Cosem primary care centres acquired in June 2024. Revenue growth of 2.7% on a like-for-like...
Nasdaq GlobeNewswire
27/08/2025

Endoscopic Submucosal Dissection/ESD Market worth US$0.75 billion by 2030 with…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116451960 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116451960 Browse in-depth TOC on "Endoscopic Submucosal Dissection Market" 197 - Tables 57 - Figures 234 - Pages By product,the endoscopic submucosal dissection (ESD) market is categorized based on product types into gastroscopes & endoscopes, knives, injection agents, tissue retractors,...
PR Newswire
27/08/2025

Protein A Resin Market worth US$2.0 billion by 2030 with 6.5% CAGR |…

Browse in-depth TOC on "Protein A Resin Market"300 - Tables120 - Figures400 - Pages Browse in-depth TOC on "Protein A Resin Market" 300 - Tables 120 - Figures 400 - Pages By product,the protein A resin market is divided into bulk resin, pre-packed columns, lab-scale columns, and others. Unlike pre-packed formats, bulk resin is the industry standard for high-volume purification processes carried out in stainless-steel column setups. Although it requires in-house packing and...
PR Newswire
27/08/2025

Drug-Eluting Stent Market to Hit USD 9.47 Billion by 2030, Says Mordor…

The global drug-eluting stent (DES) market is undergoing a period of transformation, with several emerging trends influencing growth, competition, and adoption across healthcare systems. From procedure backlogs and technology upgrades to evolving reimbursement policies and demographic shifts, these factors are redefining how hospitals, physicians, and manufacturers engage with this critical segment of cardiac care. The global drug-eluting stent (DES) market is undergoing a period of...
PR Newswire
27/08/2025

Bioretec Appoints Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer

"Sarah brings extensive commercial and management experience in healthcare, including the successful global introduction of new technologies. Her leadership was clearly demonstrated during her time as interim CEO, when she advanced the company's strategic direction," said Kustaa Poutiainen, Chairperson of the Board of Directors of Bioretec. "We look forward to Sarah leading Bioretec towards our goal of becoming a global market leader in breakthrough absorbable orthopedic…
PR Newswire
27/08/2025

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering…

Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac careAmsterdam, the Netherlands –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image quality and artificial intelligence (AI), including newly...
Nasdaq GlobeNewswire
27/08/2025

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by…

Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of factors, including an aging population and increasing body mass index (BMI).The study estimates that by 2050, OSA will affect...
Nasdaq GlobeNewswire
27/08/2025

Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA…

For patients, these advances mean clearer visualization of tiny blood vessels in the heart, earlier detection of small tumors, more accurate identification of neurological conditions, and safer lung examinations with reduced exposure to radiation. The system's ultra-high resolution also helps doctors detect diseases at earlier stages, when treatment can be more effective and outcomes significantly improved. For patients, these advances mean clearer visualization of tiny blood vessels in the...
PR Newswire
27/08/2025

MS Pharma Establishes MENA's First Biologics Manufacturing Hub in Saudi Arabia…

The factory is designed to meet the highest international regulatory standards, including EMA and US FDA, and specializes in monoclonal antibodies and complex peptides — two of the most in-demand biologic treatment classes worldwide. The plant also features the region's first in-house bioanalytical testing laboratories, eliminating the need for overseas testing services and accelerating time-to-market for critical treatments. The factory is designed to meet the highest international…
PR Newswire
27/08/2025

Evaxion to present at several conferences during the second half of 2025

Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming monthsCOPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025.Further to presenting, Evaxion will engage with...
Nasdaq GlobeNewswire
27/08/2025

Minovia Therapeutics Announces $350,000 Grant from Countdown for a Cure…

Minovia Chief Scientific Officer Dr. Noa Sher, commented, “We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood-based functional mitochondrial biomarkers. These biomarkers will enable identification of patients who may benefit from our mitochondrial augmentation technology, or MAT, proprietary platform, as well as patient follow-up after MAT treatment. Given how critical mitochondria are to human health, we...
Nasdaq GlobeNewswire
27/08/2025

Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only…

- Timing of Zemcelpro® availability in individual countries will depend on several factors, including the completion of national reimbursement procedures - Timing of Zemcelpro ®availability in individual countries will depend on several factors, including the completion of national reimbursement procedures - Cordex Biologics, an ExCellThera company, is actively seeking strategic partnerships to accelerate the commercialization of Zemcelpro ®inEuropeand other markets MONTREAL...
PR Newswire
27/08/2025

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal…

Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, addressing 85% of CRC cases with limited treatment options The OBERTO-202 study will be conducted as an investigator-led trial at Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, with Prof. Sebastian Stintzing as principal investigator and in collaboration with 14 other leading academic hospitals. The trial...
Nasdaq GlobeNewswire
27/08/2025

Adcendo ApS to Participate in Upcoming September Investor Conferences

Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive…
PR Newswire
27/08/2025
Altri  Comunicati